The theme of this year’s World AIDS Day captures the spirit: Hands Up for HIV Prevention. At AVAC, we’re delighted to see the focus on this critical area of the global response. Our new issue of Px Wire provides specifics on some hot topics for advocacy before, on and after World AIDS Day.
Px Wire October-December 2016, Vol. 9, No. 4
HIV Prevention Research & Development Investments, 2000–2015: Investment priorities to fund innovation in a challenging global health landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2015, reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.20 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC and PMTCT declined.
HIV Prevention Research & Development Investments, 2000–2015: Investment priorities to fund innovation in a challenging global health landscape (1-pager)
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2015, reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.20 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC and PMTCT declined.
Trial Participants by Prevention Research Area, 2015
Given the higher rates of acquisition seen across so-called key populations—members of highly burdened and underserved groups—it is critical to provide access to the research process such that they can participate and reap more immediate benefit of scientific progress. Greater efforts must be made to include key populations in this crucial process for the HIV prevention response to be truly impactful.
Global HIV Prevention R&D Investments by Technology, 2000-2015
In 2015, global funding for HIV prevention R&D declined slightly, from US $1.25 billion in 2014 to US $1.20 billion in 2015. This continues a decade of roughly flat funding. The US public sector remained the largest global contributor at US $850 million, and together with the Bill & Melinda Gates Foundation, the largest philanthropic funder, constituted 81 percent of all funding.
Slow and Steady Won’t Win the Prevention Race
Progress in voluntary medical male circumcision has made significant gains but still fell short of targets—or why VMMC isn’t a global priority and how to make it one. Excerpted from AVAC Report 2016: Big Data, Real People.
PrEP for MSM in Africa: Meeting Summary and Next Steps
Advocates gather in South Africa for the continent’s first PrEP and MSM consultation to chart a path for PrEP access. See the report summary with links to presentations and country plans.
Programs but Not Yet Platforms: The peril and promise of women’s biomedical HIV prevention in 2016
The benefits of PrEP is winning over support from international bodies and an increasing number of national governments. PrEP introduction is advancing on several fronts, but all this momentum has yet to impact some of the people who need it most, in particular, adolescent girls and young women with high risk of acquiring HIV. Check out our up-close look at the issue from AVAC 2016’s Big Data, Real People.
MPT Product Development: Many possibilities for MPT development
This table shows the indication (prevention effect the product is designed to have—e.g., pregnancy or one or more STIs) the way it will be delivered (e.g., through vaginal gel, pill or injection), how it might work to provide preventive effect (for example, as a physical barrier to prevent fluid exchange or as a hormonal contraceptive) and what kind of dosage could be possible (e.g., daily pill or application, sustained through the blood or around sex).
Excerpted from the MPTs factsheet.
New Analysis on Hormonal Contraception and HIV: WHO and others must act
An update excerpted from AVAC Report 2016: Big Data, Real People.